Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia

@article{Fink2020BenefitsAH,
  title={Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia},
  author={H. Fink and Eric J. Linskens and R. Macdonald and Pombie C Silverman and J. McCarten and Kristine M C Talley and Mary L. Forte and Priyanka Desai and Victoria A. Nelson and M. Miller and L. Hemmy and M. Brasure and B. Taylor and W. Ng and Jeannine M Ouellette and Kerry M. Sheets and T. Wilt and M. Butler},
  journal={Annals of Internal Medicine},
  year={2020},
  volume={172},
  pages={656 - 668}
}
Background Effects of drug treatment of clinical Alzheimer-type dementia (CATD) are uncertain. Purpose To summarize evidence on the effects of prescription drugs and supplements for CATD treatment. Data Sources Electronic bibliographic databases (inception to November 2019), ClinicalTrials.gov (to November 2019), and systematic review bibliographies. Study Selection English-language trials of prescription drug and supplement treatment in older adults with CATD that report cognition… Expand
2 Citations

References

SHOWING 1-10 OF 102 REFERENCES
Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease: A Randomized, Placebo-Controlled Study
  • 132
  • Highly Influential
Pimavanserin in Alzheimer’s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms
  • 10
  • Highly Influential
  • PDF
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
  • E. Peskind, S. Potkin, +4 authors S. McDonald
  • Psychology, Medicine
  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2006
  • 275
...
1
2
3
4
5
...